Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722173 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
ElectronicAdd to Basket
Hard CopyAdd to Basket



Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter
Espicom Business Intelligence Ltd, Nov 2009, Pages: 160


  Description  
  Table of Contents  
  Summary  
    
    
   
 Enquire before Buying  
 Send to a Friend  

The prostate cancer market is on the verge of considerable change with the imminent arrival of new targeted therapies that will prolong patient survival.

Prostate cancer (PCA) is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancer death in men. In the US, over two million men currently suffer with PCA and it is estimated that there were 192,311 new cases and 29,698 deaths due to the disease in 2008. There have been dramatic improvements in PCA survival over the last 25 years, mainly due to a combination of earlier diagnosis and improvements in treatments, although rates vary between countries.

The PCA market was estimated to be worth US$5.2 billion in 2008; it is one of the larger segments of the oncology market, alongside breast, non-small cell lung and colorectal cancers. The market is currently driven by the use of hormonal therapies, which are prescribed mainly for advanced hormone-dependent PCA, and include AstraZeneca’s Zoladex (goserelin) and Casodex (bicalutamide), Abbott/Takeda’s Lupron/Lupron Depot (leuprolide subcutaneous injection or intramuscular depot) and sanofi-aventis/Astellas Pharma’s Eligard (leuprolide subcutaneous depot). In addition, sanofi-aventis’ Taxotere (docetaxel) has become the standard treatment for hormone-refractory prostate cancer (HRPCA).

However, the market dynamics will change considerably over the next six years as patents expire and generic competition intensifies. Research into new therapies is extremely active and new agents with novel modes of action are being evaluated in clinical trials, including Dendreon’s Provenge, which is likely to be the first therapeutic cancer vaccine to market, and Bristol-Myers Squibb’s fully-human monoclonal antibody, ipilimumab. Other companies are extending existing products’ indications into PCA, with Roche’s angiogenesis inhibitor, Avastin (bevacizumab), and GlaxoSmithKline’s preventative treatment, Avodart (dutasteride), as the most notable examples.

The analyst estimates that sales of prostate cancer treatments will increase to over US$7.7 billion by 2015, with a compound annual growth rate of 5.9%

There is currently a huge interest in developing new treatments for PCA, with 96 drugs estimated to be in clinical development. The majority of these are the new targeted therapies, including small-molecule tyrosine kinase inhibitors, monoclonal antibodies and therapeutic vaccine candidates. In addition to the development of novel products, some companies are seeking to optimise the life-cycle of drugs already approved in other indications such as Roche’s Avastin (bevacizumab), Pfizer’s Sutent (sunitinib) and Novartis’ Glivec/Gleevec (imatinib).

Hormone-refractory prostate cancer (HRPCA) – a focus of attention
Market opportunities are largest for novel treatment strategies that prolong survival. Many of the new targeted approaches are focused on the treatment of hormone-refractory PCA (HRPCA), an area where, up until the recent approval of Taxotere, there were very few options for patients. Whereas previous research has focused mainly on the hormone-dependency of PCA, the rationale for new drugs coming through research is based on the increasing knowledge of the molecular abnormalities underlying PCA.

The arrival of innovative targeted therapies will not make traditional hormonal or chemotherapies redundant. Rather, targeted therapies will be used in combination with traditional therapies and each other. The limits to combinations will likely be cost, as the novel therapies can be expected to be comparable to recently-launched novel therapies in other cancers, for example Avastin at over US$50,000 per annum.

Shape of the industry in 2008...
The PCA market is currently dominated by a handful of pharmaceutical companies, the most significant of which is AstraZeneca. In 2008, AstraZeneca had a 41% share of the PCA market through the marketing of the LHRH analogue, Zoladex, and the anti-androgen, Casodex. AstraZeneca’s leadership position has been untouchable for many years and is primarily due to the combined androgen blockade therapeutic approach in PCA and expanded licenses for both advanced and locally-advanced PCA in some markets.

...and in 2015
With the advent of the new targeted therapies, the PCA market will change considerably by 2015. In 2008, most drug treatment occurred in the advanced hormone-responsive PCA market segment. By 2015, we expect the balance to shift to the HRPCA segment of the PCA market as more effective products are introduced and combined to address the unmet clinical need for patients in this sector. In addition, there will be significant opportunities to expand within the early PCA market. In addition to HRCPA treatments, Dendreon’s novel therapeutic cancer vaccine, Provenge, should achieve blockbuster sales and ensure a substantial market share for the company.



Customers who bought this item also bought

Prostate Cancer Therapeutics - Global Strategic Business Report

Prostate Cancer Therapeutics - A Global Market Perspective

Prostate Cancer Therapeutics - A Global Market Perspective

Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs

Prostate Cancer - A Therapeutic & Competitive Insight

Antibody Drug Targets and Focus on Breast & Prostate Cancer

Strategic Perspectives: Prostate Cancer - Issues in Second-line, Brachytherapy and Hormone-Refractory Prostate Cancer Treatments

Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer

Stakeholder Insight: Prostate Cancer Treatment and Commercial Issues

Prostate and Breast Cancer- New Treatments & Developmental Progress

Chinese Markets for Prostate Cancer Treatment Drugs

Prostate Cancer - A Prostrate Market Waiting For Innovations



Top of page


   All rights reserved. � Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds